Progestogens and pregnancy loss

References

• Martel D, Monier MN, Roche D, Psychoyos A. Hormonal dependence of pinopode formation at the uterine luminal surface. Hum Reprod 1991;6:597–603
   PubMed Web of Science ®Google Scholar
• Psychoyos A. Uterine receptivity for nidation. Ann N Y Acad Sci 1986;476:36–42
   PubMed Web of Science ®Google Scholar
• Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14:353–6
   PubMedGoogle Scholar
• Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 2000;15:713–18
   PubMed Web of Science ®Google Scholar
• Schumacher A, Dauven D, Zenclussen AC. Progesterone-driven local regulatory T cell induction does not prevent fetal loss in the CBA/J × DBA/2J abortion-prone model. Am J Reprod Immunol 2017;77:e12626
   Web of Science ®Google Scholar
• Szekeres-Bartho J, Barakonyi A, Polgar B, et al. The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol 1999;42:44–8
   PubMed Web of Science ®Google Scholar
• Arck PC, Rücke M, Rose M, et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008;17:101–13
   PubMed Web of Science ®Google Scholar
• Hudić I, Fatusić Z. Progesterone - induced blocking factor (PIBF) and Th(1)/Th(2) cytokine in women with threatened spontaneous abortion. J Perinat Med 2009;37:338–42
   PubMed Web of Science ®Google Scholar
• Bogdan A, Berta G, Szekeres-Bartho J. PIBF positive uterine NK cells in the mouse decidua. J Reprod Immunol 2017;119:38–43
   PubMed Web of Science ®Google Scholar
• Chernyshov VP, Vodyanik MA, Pisareva SP. Lack of soluble TNF-receptors in women with recurrent spontaneous abortion and possibility for its correction. Am J Reprod Immunol 2005;54:284–91
   PubMed Web of Science ®Google Scholar
• Wolfson ML, Schander JA, Bariani MV, Correa F, Franchi AM. Progesterone modulates the LPS-induced nitric oxide production by a progesterone-receptor independent mechanism. Eur J Pharmacol 2015;769:110–16
   PubMed Web of Science ®Google Scholar
• Arrowsmith S, Kendrick A, Wray S. Drugs acting on the pregnant uterus. Obstet Gynaecol Reprod Med 2010;20:241–7
   PubMedGoogle Scholar
• Andronowska A, Chruściel M. Influence of estradiol-17β and progesterone on nitric oxide (NO) production in the porcine endometrium during first half of pregnancy. Reprod Biol 2008;8:43–55
   PubMed Web of Science ®Google Scholar
• Czajkowski K, Sienko J, Mogilinski M, Bros M, Szczecina R, Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 2007;87:613–18
   PubMed Web of Science ®Google Scholar
• Huybayter ZR, Muasher SJ. Luteal supplementation in in vitro fertilization: more questions than answers. Fertil Steril 2008;89:749–58
   PubMed Web of Science ®Google Scholar
• Huytchinson-Williams KA, Lunenfeld B, Diamond MP, Lavy G, Boyers SP, DeCherney AH. Human chorionic gonadotropin, estradiol, and progesterone profiles in conception and non-conception cycles in an in vitro fertilization program. Fertil Steril 1989;52:441–5
   PubMed Web of Science ®Google Scholar
• Forman RG, Eychenne B, Nessmann C, Frydman R, Robel P. Assessing the early luteal phase in-vitro fertilization cycles: relationships between plasma steroids, endometrial receptors, and endometrial histology. Fertil Steril 1989;51:310–16
   PubMed Web of Science ®Google Scholar
• Li TC, Tuckerman EM, Laird SM. Endometrial factors in recurrent miscarriage. Hum Reprod Update 2002;1:43–52
   Google Scholar
• van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011;7:CD009154
   Google Scholar
• Edmonds DK, Lindsay KS, Miller JF, Williamson E, Wood PJ. Early embryonic mortality in women. Fertil Steril 1982;38:447–53
   PubMed Web of Science ®Google Scholar
• Rubio C, Rodrigo L, Pérez-Cano I, et al. FISH screening of aneuploidies in preimplantation embryos to improve IVF outcome. Reprod Biomed Online 2005;11:497–506
   PubMed Web of Science ®Google Scholar
• Csapo AI, Pulkkinen MO, Ruttner B, Sauvage JP, Wiest WG. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol 1972;112:1061–7
   PubMed Web of Science ®Google Scholar
• Babalioglu R, Varol FG, Ilhan R, Yalcin O, Cizmecioglu F. Progesterone profiles in luteal-phase defects associated with recurrent spontaneous abortions. J Assist Reprod Genet 1996;13:306–9
   PubMed Web of Science ®Google Scholar
• Li TC, Spuijbroek MD, Tuckerman E, Anstie B, Loxley M, Laird S. Endocrinological and endometrial factors in recurrent miscarriage. Bjog 2000;107:1471–9
   PubMed Web of Science ®Google Scholar
• Stovall TG, Ling FW, Carson SA, Buster JE. Serum progesterone and uterine curettage in differential diagnosis of ectopic pregnancy. Fertil Steril 1992;57:456–7
   PubMed Web of Science ®Google Scholar
• Al-Sebai MA, Kingsland CR, Diver M, Hipkin L, McFadyen IR. The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. Br J Obstet Gynaecol 1995;102:364–9
   PubMedGoogle Scholar
• Saccone G, Schoen C, Franasiak JM, Scott RT, Jr., Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril 2017;107:430–8
   PubMed Web of Science ®Google Scholar
• Coomarasamy A, Williams H, Truchanowicz E, et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med 2015;373:2141–8
   PubMed Web of Science ®Google Scholar
• Carp HJA. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015;31:422–30
   PubMed Web of Science ®Google Scholar
• Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011;(12):CD005943
   Web of Science ®Google Scholar
• Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil 2014;15:147–51
   PubMedGoogle Scholar
• Carp HJA. Progestogens in the prevention of miscarriage. Horm Mol Biol Clin Investig 2016;27:55–62
   PubMed Web of Science ®Google Scholar
• Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28:983–90
   PubMed Web of Science ®Google Scholar
• Sauebrei EE. Early pregnancy: pre-embrionic and embrionic periods. In: Sauebrei EE, Nguyen KT, Nolan RL, editors. A practical guide to ultrasound in obstetrics and gynecology. Philadelphia (PA): Lippincott-Raven Publishers; 1999. p. 122–31
   Google Scholar
• Tuuli MG, Norman SM, Odibo AO, Macones GA, Cahill AG. Perinatal outcomes in women with subchorionic hematoma: a systematic review and meta-analysis. Obstet Gynecol 2011;117:1205–12
   PubMed Web of Science ®Google Scholar
• Pelinescu-Onciul D, Radulescu-Botica R, Steriu M, Cheles C, Varlas V. Terapia cu progesteron micronizat a hematoameloreciduale. Infomedica 1999;2S:32–5
   Google Scholar
• Pelinescu-Onciul D. Subchorionic hemorrhage treatment with dydrogesterone. Gynecol Endocrinol 2007;23(Suppl 1):77–81
   PubMed Web of Science ®Google Scholar
• Martin JA, Hamilton BE, Osterman MJK, Curtin SC, Mathews TJ. Centers for disease control and prevention national center for health statistics national vital statistics system births: final data for 2013. Natl Vital Stat Rep 2015;64:1–68
   Google Scholar
• Jacobsson B, Mattsby-Baltzer I, Andersch B, et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women in preterm labor. Acta Obstet Gynecol Scand 2003;82:120–8
   PubMed Web of Science ®Google Scholar
• Hudić I, Szekeres-Bartho J, Fatušić Z, et al. Dydrogesterone supplementation in women with threatened preterm delivery-the impact on cytokine profile, hormone profile, and progesterone-induced blocking factor. J Reprod Immunol 2011;92:103–10
   PubMed Web of Science ®Google Scholar
• Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149–54
   PubMedGoogle Scholar
• Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–85
   PubMed Web of Science ®Google Scholar
• Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 2013;(7):CD004947
   PubMed Web of Science ®Google Scholar
• Norman JE, Marlow N, Messow CM, et al. OPPTIMUM study group. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 2016;387:2106–16
   PubMed Web of Science ®Google Scholar
• Romero R, Nicolaides KH, Conde-Agudelo A, et al. Vaginal progesterone decreases preterm birth ≤34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta‐analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol 2016;48:308–17
   PubMed Web of Science ®Google Scholar
• Romero R, Conde-Agudelo A, El-Refaie W, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017;49:303–14
   PubMed Web of Science ®Google Scholar
• Oler E, Eke AC, Hesson A. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery. Int J Gynecol Obstet 2017;138:12–16
   PubMed Web of Science ®Google Scholar
• Saccone G, Khalifeh A, Elimian A, et al. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2017;49:315–21
   PubMed Web of Science ®Google Scholar
• Whalen RE, Peck CK, LoPiccolo J. Virilization of female rats by prenatally administered progestin. Endocrinology 1966;78:965–70
   PubMed Web of Science ®Google Scholar
• Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005;159:957–62
   PubMedGoogle Scholar
• Michaelis J, Michaelis H, Glück E, Koller S. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology 1983;27:57–64
   PubMedGoogle Scholar
• Zaqout M, Aslem E, Abuqamar M, Abughazza O, Panzer J, De Wolf D. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr Cardiol 2015;36:1483–8
   PubMed Web of Science ®Google Scholar
• Tikkanen J, Heinonen OP. Congenital heart disease in the offspring and maternal habits and home exposures during pregnancy. Teratology 1992;46:447–54
   PubMedGoogle Scholar
• Shi H, Yang S, Liu Y, et al. Study on environmental causes and SNPs of MTHFR, MS and CBS genes related to congenital heart disease. PLoS One 2015;10:e0128646
   PubMed Web of Science ®Google Scholar
• Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev 2009;85:375–77
   PubMed Web of Science ®Google Scholar